Research

The “Triple-G” Miracle: Tracking Retatrutide's Record-Breaking TRIUMPH Trials

August 20, 20266 min read

If you have paid attention to health news lately, you know that weight-loss medications like Ozempic and Wegovy have completely changed how we treat obesity. But while those drugs are making history today, scientists are already working on what comes next.

Enter retatrutide, a new experimental drug from Eli Lilly. It is nicknamed the “Triple-G” molecule because it targets three different metabolic receptors in your body at the same time. The massive clinical testing program for this drug is called the TRIUMPH trials. ^{[1, 2, 3, 4, 5]}

The results coming out of these trials show weight loss that doesn't just beat current drugs—it actually matches the results of weight-loss surgery. Let's break down how this drug works, how the trials are going, and what this means for the future. ^{[1, 2]}

What Makes Retatrutide Different?

To understand why retatrutide is such a big deal, it helps to look at the evolution of these weight-loss drugs: ^{[1, 2]}

• Ozempic / Wegovy (Semaglutide): Hits one receptor (GLP-1) to mimic gut hormones, slow down your digestion, and tell your brain you are full. ^{[1, 2, 3, 4, 5]}
• Mounjaro / Zepbound (Tirzepatide): Hits two receptors (GLP-1 + GIP). This extra step supercharges the weight loss and helps quiet “food noise” even more. ^{[1, 2, 3, 4, 5]}
• Retatrutide: Hits three receptors (GLP-1 + GIP + Glucagon). ^{[1, 2, 3]}

That third target—glucagon—is the secret weapon. While the first two targets focus on turning down your appetite, glucagon tells your liver to actively burn fat reserves and increases the number of calories your body burns while at rest. ^{[1, 2, 3, 4]}

Tracking the TRIUMPH Progress

The TRIUMPH program is a massive global puzzle made up of several different trials, each testing retatrutide on a different group of people. The core trials evaluated patients using a weekly 12 mg maximum dose over long periods. ^{[1, 2, 3, 4, 5]}

Table 1: At-a-Glance Results from the Main TRIUMPH Trials

Visualizing the Weight-Loss Leap

When you map out the data, you can see how much further retatrutide pushes the boundaries compared to older generations of weight-loss medications.

What About Side Effects?

Like any medication, retatrutide isn't perfect. Because it is so powerful, it can be tough on the body, especially when patients first start taking it. ^{[1, 2, 3, 4]}

The Usual Gut Troubles

The most common side effects are identical to Ozempic: nausea, diarrhea, constipation, and vomiting. These symptoms usually happen when a person increases their dose. ^{[1, 2]}

To combat this, the TRIUMPH trials use a strict, slow titration plan:

2 mg  →  4 mg  →  6 mg  →  9 mg  →  12 mg

Patients stay on each dose step for 4 weeks to give their stomach time to adjust. ^{[1, 2, 3, 4, 5]}

Table 2: Dose vs. Dropouts (Finding the Sweet Spot)

Not everyone needs—or can handle—the maximum 12 mg dose. The trials showed that lower doses still provide incredible results with fewer side effects. ^{[1, 2, 3]}

The Glucagon Heart Rate Spike

Because glucagon interacts directly with the heart, retatrutide causes a temporary increase in resting heart rate (usually an extra 5 to 10 beats per minute) that peaks around month six of treatment. Thankfully, the data shows this heart rate spike naturally goes back down toward baseline by the end of the trial, and it has not caused any major cardiovascular safety issues. ^{[1, 2, 3]}

When Can You Get It?

With the primary trials wrapping up successfully, Eli Lilly is preparing to submit the official data package to global health regulators like the US FDA in early 2027. ^{[1, 2, 3]}

Because review processes take time, retatrutide will likely not be approved or available in pharmacies until late 2027 or early 2028. In the meantime, researchers are running a secondary trial called TRIUMPH-9 to test even gentler dose schedules, trying to lower that 11.3% dropout rate so more people can successfully stay on the drug. ^[1]

Retatrutide proves that we are moving past basic appetite suppression. The future of metabolic health is about actively changing how our bodies use and burn energy. ^[1]

References

1. Wilding, J. P. H., et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” The New England Journal of Medicine, 384(11), 989-1002.
2. Jastreboff, A. M., et al. (2023). “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicine, 389(6), 514-526.
3. Eli Lilly and Company. (2025). TRIUMPH-4 Topline Efficacy Data: Efficacy and Safety of Retatrutide in Patients with Knee Osteoarthritis. Lilly Investor Press Releases.
4. Eli Lilly and Company. (2026). Lilly's Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial (TRIUMPH-1). Lilly Media Release.
5. Eli Lilly and Company. (2026). Lilly Announces Successful Outcomes for TRIUMPH-2 and TRIUMPH-3 Phase 3 Clinical Trials. Disclosed July 23, 2026.
6. Giblin, G., et al. (2026). “The Emerging Landscape of Triple-Agonist Therapies: A Focus on the TRIUMPH Clinical Trial Layout.” Diabetes, Obesity and Metabolism, 28(3), 142-155.